| Story Views | |
| Now: | |
| Last Hour: | |
| Last 24 Hours: | |
| Total: | |
CytomX Therapeutics shoots higher as it’s set for US$200mln upfront payment from Bristol-Myers Squibb
CytomX Therapeutics Inc (NASDAQ:CTMX) saw its shares shoot almost 25% higher in early New York trading after the biotech firm said it would receive a US$200mln upfront payment from drugs giant Bristol-Myers Squibb Co. (NYSE:BMY).
The payment is part of the expansion of a collaboration pact to discover cancer treatments using CytomX’s Probody platform.
CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
Bristol-Myers’ head of discovery, Carl Decicco, said: “CytomX’s Probody platform has enhanced our discovery research as we seek to direct the therapeutic effects of immunotherapy in a more targeted approach against tumor.”
CytomX’s shares, which have gained 32% over the past three months, were up 23.7% to US$18.78 in early morning trade.
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/175079/cytomx-therapeutics-shoots-higher-as-it-s-set-for-us200mln-upfront-payment-from-bristol-myers-squibb-175079.html
